Direkt zum Inhalt
  1. Publizieren |
  2. Suche |
  3. Browsen |
  4. Neuzugänge rss |
  5. Open Access |
  6. Rechtsfragen |
  7. EnglishCookie löschen - von nun an wird die Spracheinstellung Ihres Browsers verwendet.

Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis

Heublein, Sabine ; Mayr, Doris ; Meindl, Alfons ; Kircher, Alexandra ; Jeschke, Udo ; Ditsch, Nina

In: Journal of Experimental & Clinical Cancer Research, 36 (2017), Nr. 57. S. 1-11. ISSN 1756-9966

[thumbnail of 13046_2017_Article_517.pdf]
Vorschau
PDF, Englisch
Download (3MB) | Lizenz: Creative Commons LizenzvertragVitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis von Heublein, Sabine ; Mayr, Doris ; Meindl, Alfons ; Kircher, Alexandra ; Jeschke, Udo ; Ditsch, Nina steht unter einer Creative Commons Namensnennung 3.0 Deutschland

Zitieren von Dokumenten: Bitte verwenden Sie für Zitate nicht die URL in der Adresszeile Ihres Webbrowsers, sondern entweder die angegebene DOI, URN oder die persistente URL, deren langfristige Verfügbarkeit wir garantieren. [mehr ...]

Abstract

Background: BRCA1 mutated breast cancers are commonly diagnosed as negative for classical hormone receptors i.e. estrogen receptor, progesterone receptor and/or Her2. Due to these common targets being absent the application of anti-endocrine therapies is rather limited and a certain focus has been set on discovering alternative target molecules. We recently highlighted thyroid hormone receptors (TRs) to predict prognosis in breast cancer patients that had been diagnosed a BRCA1 germline mutation. Vitamin D Receptor (VDR), Retinoid X Receptor (RXR) and Peroxisome Proliferator-activated Receptor γ (PPARγ) are known to interact with TRs by forming functional heterodimers. Whether VDR, RXR or PPARγ are expressed in BRCA1 mutated breast cancer or may even be present in case of triple negativity is not known. Hence the current study aimed to investigate VDR, RXR and PPARγ in BRCA1 mut breast cancer and to test whether any of the three may be associated with clinico-pathological criteria including overall survival. Methods: This study analyzed VDR, RXR and PPARγ by immunohistochemistry in BRCA1 associated (n = 38) and sporadic breast cancer (n = 79). Receptors were quantified by applying an established scoring system (IR-score) and were tested for association with clinico-pathological variables. Results: VDR, RXR and PPARγ were detected in over 90% of triple negative BRCA1 mut breast cancer and were significantly (VDR: p < 0.001, RXR: p = 0.010, PPARγ: p < 0.001) overexpressed in BRCA1 mutated as compared to sporadic cancer cases. VDR and RXR positivity predicted prolonged overall survival only in BRCA1 mutated cases while such association was not observed in sporadic breast cancer. Conclusions: In conclusion, this is the first study to describe VDR, RXR and PPARγ in BRCA1 mutated breast cancer. Based on the data presented here these receptors may be hypothesized to potentially evolve as interesting markers or even targets in hereditary breast cancer. However, independent studies are indispensable thus to confirm this hypothesis.

Dokumententyp: Artikel
Titel der Zeitschrift: Journal of Experimental & Clinical Cancer Research
Band: 36
Nummer: 57
Verlag: BioMed Central; Springer
Ort der Veröffentlichung: London; Berlin; Heidelberg
Erstellungsdatum: 26 Apr. 2017 08:49
Erscheinungsjahr: 2017
ISSN: 1756-9966
Seitenbereich: S. 1-11
Institute/Einrichtungen: Medizinische Fakultät Heidelberg und Uniklinikum > Universitäts-Frauenklinik
DDC-Sachgruppe: 610 Medizin
Leitlinien | Häufige Fragen | Kontakt | Impressum |
OA-LogoDINI-Zertifikat 2013Logo der Open-Archives-Initiative